var data={"title":"Romiplostim: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Romiplostim: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/364510?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=romiplostim-patient-drug-information\" class=\"drug drug_patient\">see &quot;Romiplostim: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470287\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nplate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7983804\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nplate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470291\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Colony Stimulating Factor;</li>\n      <li>\n        Hematopoietic Agent;</li>\n      <li>\n        Thrombopoietic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470496\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use the lowest dose sufficient to maintain platelet count &ge;50,000/mm<sup>3</sup> as necessary to reduce the risk of bleeding. Do not use to normalize platelet counts.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic immune thrombocytopenia (ITP):</b> SubQ: Initial: 1 mcg/kg once weekly (based on actual body weight); adjust dose by 1 mcg/kg/week increments to achieve platelet count &ge;50,000/mm<sup>3</sup> and to reduce the risk of bleeding; Maximum dose: 10 mcg/kg/week (median dose needed to achieve response in clinical trials: 2 mcg/kg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Dosage adjustment recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adjust dose based on platelet count response:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &lt;50,000/mm<sup>3</sup>: Increase weekly dose by 1 mcg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &gt;200,000/mm<sup>3</sup> for 2 consecutive weeks: Reduce weekly dose by 1 mcg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Platelet count &gt;400,000/mm<sup>3</sup>: Withhold dose; assess platelet count weekly; when platelet count &lt;200,000/mm<sup>3</sup>, resume with the weekly dose reduced by 1 mcg/kg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinue if platelet count does not respond to a level that avoids clinically important bleeding after 4 weeks at the maximum recommended dose of 10 mcg/kg/week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470497\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13464221\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13464220\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470502\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nplate: 250 mcg (1 ea); 500 mcg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470289\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874969\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088667.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRl+hOl1rbOifsqqtMpKNGVUg==&amp;TOPIC_ID=9493\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088667.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470498\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer SubQ. Administration volume may be small; use appropriate syringe (with graduations to 0.01 mL) for administration. Verify calculations, final concentration, and volume drawn up for administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470293\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic immune thrombocytopenia:</b> Treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had insufficient response to corticosteroids, immune globulin, or splenectomy </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Limitations of use: Should be used only when the degree of thrombocytopenia and clinical condition increase the risk for bleeding; should not be used in attempt to normalize platelet counts; <b>not</b> indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome or any cause of thrombocytopenia other than chronic ITP. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9601128\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">RomiPLOStim may be confused with romiDEPsin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470355\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (35%), dizziness (17%), insomnia (16%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (26%), myalgia (14%), limb pain (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Paresthesia (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dyspepsia (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Thrombocytopenia (7%; rebound)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody formation (&le;4%; no correlation between antibody development and drug safety or efficacy has been established)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Shoulder pain (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Myelofibrosis (bone marrow reticulin formation/deposition)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, erythromelalgia, hypersensitivity reaction, myelofibrosis (marrow fibrosis with collagen), thromboembolism, thrombosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470298\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to romiplostim or any component of the formulation; known history of sensitivity or allergy to any <i>E. coli</i>-derived product.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470299\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow reticulin: May increase the risk for bone marrow reticulin formation or progression; this formation may improve upon discontinuation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Progression  from existing myelodysplastic syndrome (MDS) to acute myeloid leukemia (AML) has been observed in clinical trials studying romiplostim for severe thrombocytopenia associated with MDS (not an approved indication); a higher percentage of patients receiving romiplostim experienced transformation to AML (compared to placebo). An increase in the percentage of circulating myeloblasts in peripheral blood counts  was also noted (both in patients who progressed to AML and in those who did not); blast cells decreased to baseline after discontinuation in some patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolism: Thromboembolism or thrombotic complications may occur with increased platelets. Follow dosage adjustment recommendations to minimize the risk for thrombotic or thromboembolic complications. Use with caution in patients with a history of cerebrovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with chronic liver disease; portal vein thrombosis has been reported in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant ITP medications: May be used in combination with other therapies for ITP, including corticosteroids, danazol, azathioprine, immune globulin, or Rho(D) immune globulin. Reduce dose of or discontinue ITP medications when platelet count &ge;50,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Indicated only when the degree of thrombocytopenia and clinical conditions increase the risk for bleeding; use the lowest dose necessary to achieve and maintain platelet count &ge;50,000/mm<sup>3</sup>. Do not use to normalize platelet counts. Discontinue if platelet count does not respond to a level to avoid clinically important bleeding after 4 weeks at the maximum recommended dose. Not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia  other than chronic ITP. Only use in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation: Upon discontinuation of therapy, rebound thrombocytopenia and risk of bleeding may develop. Severity may be greater than pretreatment level. Monitor CBCs and platelet counts weekly for at least 2 weeks after discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Error prevention: Overdose may result in thrombotic/thromboembolic complications due to excessive platelet levels; underdose may result in lack of platelet response and potential for bleeding. Use caution when calculating dose and appropriate volume for administration (volume may be very small; administer with syringe that allows for 0.01 mL graduations).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyporesponsiveness: Lack of response or failure to maintain platelet response should trigger investigation in to causative factors, including neutralizing antibodies to romiplostim.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300015\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6708337\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9493&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470294\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470295\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Use during pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women exposed to romiplostim during pregnancy are encouraged to enroll in the Nplate pregnancy (1-800-772-6436). In Canada, women who become pregnant during treatment are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (1-866-512-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13269694\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if romiplostim is present in breast milk. Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made to discontinue breastfeeding or romiplostim, taking into account the importance of treatment to the mother. In Canada, women who breastfeed during treatment are encouraged to enroll in Amgen's Lactation Surveillance Program (1-866-512-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6471447\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sucrose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470500\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelets (baseline, during treatment [weekly until platelet response stable for at least 4 weeks then monthly] and weekly for at least 2 weeks following discontinuation or completion of treatment)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Evaluate for neutralizing antibodies in patients with inadequate response (blood samples may be submitted to the manufacturer for assay [1-800-772-6436]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470493\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Target platelet count of 50,000 to 200,000/mm<sup>3</sup>; platelet life span: 8 to 11 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470491\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Romiplostim is a thrombopoietin (TPO) peptide mimetic that increases platelet counts in ITP by binding to and activating the human TPO receptor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6470483\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Platelet count increase: SubQ: 4 to 9 days (Wang 2004); Peak platelet count increase: Days 12 to 16 (Wang 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Platelet counts return to baseline by day 28 (Wang 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: SubQ: Slow (Wang 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Median: 3.5 days (range: 1 to 34 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: SubQ: Median: 14 hours (range: 7 to 50 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321843\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nplate Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mcg (1): $2,165.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg (1): $4,330.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11390219\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Nplate (AE, AR, AT, AU, BB, BE, CH, CL, CR, CY, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GT, HK, HN, HR, IE, IL, IS, KR, LB, LT, LU, LV, MT, NI, NL, NO, PA, PL, PT, RO, SE, SI, SK, SV, TR);</li>\n      <li>Romiplate (JP, SG, TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bussel JB, Buchanan GR, Nugent DJ, et al, &ldquo;A Randomized, Double-Blind Study of Romiplostim to Determine Its Safety and Efficacy in Children With Immune Thrombocytopenia,&rdquo; <i>Blood</i>, 2011, 118(1):28-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/21502541/pubmed\" target=\"_blank\" id=\"21502541\">21502541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bussel JB, Kuter DJ, George JN, et al, &ldquo;AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP,&rdquo; <i>N Engl J Med</i>, 2006, 355(16):1672-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/17050891/pubmed\" target=\"_blank\" id=\"17050891\">17050891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bussel JB, Kuter DJ, Pullarkat V, et al, &ldquo;Safety and Efficacy of Long-Term Treatment With Romiplostim in Thrombocytopenic Patients With Chronic ITP,&rdquo; <i>Blood</i>, 2009, 113(10):2161-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/18981291/pubmed\" target=\"_blank\" id=\"18981291\">18981291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuter DJ, &ldquo;New Thrombopoietic Growth Factors,&rdquo; <i>Blood</i>, 2007, 109(11):4607-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/17289815/pubmed\" target=\"_blank\" id=\"17289815\">17289815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuter DJ, Bussel JB, Lyons RM, et al, &ldquo;Efficacy of Romiplostim in Patients With Chronic Immune Thrombocytopenic Purpura: A Double-Blind Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2008, 371(9610):395-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/18242413/pubmed\" target=\"_blank\" id=\"18242413\">18242413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuter DJ, Mufti GJ, Bain BJ, et al, &ldquo;Evaluation of Bone Marrow Reticulin Formation in Chronic Immune Thrombocytopenia Patients Treated With Romiplostim,&rdquo; <i>Blood</i>, 2009, 114(18):3748-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/19671919/pubmed\" target=\"_blank\" id=\"19671919\">19671919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuter DJ, Rummel M, Boccia R, et al, &ldquo;Romiplostim or Standard of Care in Patients With Immune Thrombocytopenia,&rdquo; <i>N Engl J Med</i>, 2010, 363(20):1889-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/21067381/pubmed\" target=\"_blank\" id=\"21067381\">21067381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nplate (romiplostim) [prescribing information]. Thousand Oaks, CA: Amgen; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nplate (romiplostim) [product monograph]. Mississauga, Ontario, Canada: Amgen Canada Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanz MA, Aledort L, Mathias SD, et al, &ldquo;Analysis of EQ-5D Scores From Two Phase 3 Clinical Trials of Romiplostim in the Treatment of Immune Thrombocytopenia (ITP),&rdquo; <i>Value Health</i>, 2011, 14(1):90-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/21211490/pubmed\" target=\"_blank\" id=\"21211490\">21211490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang B, Nichol JL, and Sullivan JT, &ldquo;Pharmacodynamics and Pharmacokinetics of AMG 531, a Novel Thrombopoietin Receptor Ligand,&rdquo; <i>Clin Pharmacol Ther</i>, 2004, 76(6):628-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/romiplostim-drug-information/abstract-text/15592334/pubmed\" target=\"_blank\" id=\"15592334\">15592334</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9493 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6470287\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F7983804\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6470291\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6470496\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6470497\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F13464221\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13464220\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6470502\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6470289\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874969\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6470498\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6470293\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9601128\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6470355\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6470298\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6470299\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300015\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6708337\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6470294\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6470295\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13269694\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F6471447\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6470500\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F6470493\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6470491\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6470483\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321843\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F11390219\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9493|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=romiplostim-patient-drug-information\" class=\"drug drug_patient\">Romiplostim: Patient drug information</a></li></ul></div></div>","javascript":null}